The present results suggest that breast cancer survivors with PD have worse cognitive functioning based on a cognitive screening test and lower quality of life than the PD group, and significantly higher levels of IL‐1β, TNF‐α, and IL‐4, compared to the patients with NPD. This evidence concerns the gene IL4 and breast carcinoma.